Rachel Diamant, MSc

Rachel Diamant, MSc, co-founded Emendo Biotherapeutics and is responsible for its IP strategy. She has generated an extensive patent portfolio covering various novel technologies and products while also expertly navigating the IP space. As EmendoBio’s chief business officer, Damiant builds the pipeline of clinical programs and academic and industrial collaborations and partnerships for the preclinical development of the company’s selected indications and genomic targets. She holds an MSc in neurobiology from the Weizmann Institute of Science and a biotechnology engineering degree from the Technion Israel Institute of Technology.